Literature DB >> 36160083

Potential Effects of Melatonin on TRPA1 Channels in the Prevention and Treatment of Alzheimer's Disease.

Ahmet Özşimşek1, İshak Suat Övey2.   

Abstract

Introduction: Alzheimer's disease (AD) is the most common cause of dementia and is defined as a progressive neurodegenerative disease. Main clinical features of AD are progressive impairment in learning and memory loss. Several studies have indicated that mitochondria play a critical role in the pathogenesis of AD. In this study, we investigated the effect of melatonin on mitochondria-dependent TRPA1 ion channels in neuroblastoma cells by creating an in vitro model of Alzheimer's disease.
Methods: Okadaic acid was applied to SH-SY5Y (human neuroblastoma cell line) cells to create an AD model. After cellular differentiation, the following 7 main groups were created: Group 1 (Control), Group 2 (Mel+AD), Group 3 (Mel+AD+AP18), Group 4 (AD), Group 5 (AD+AP18), Group 6 (AD+Mel), and Group 7 (AD+Mel+AP18), and Alzheimer's disease was determined in vitro by examining the effect of melatonin on calcium-dependent TRPA1 channels in neuroblastoma cells.
Results: The Ca2+concentration was greater in the melatonin+AD, AD and AD+melatonin groups than in the control (p<0.001). However, there was no statistically significant difference between Mel+AD+AP18, AD+Mel+AP18 and the control. We determined that Ca2+ levels were lower in the melatonin+AD and AD+melatonin groups than in the AD group (p<0.001 and p<0.05). Additionally, cytosolic Ca2+ concentrations were found to be lower in the melatonin+AD group than in the AD+melatonin group (p<0.05). In evaluating the apoptosis and oxidative stress levels, we found that the apoptosis and intracellular ROS values were higher in the melatonin+AD, AD and AD+melatonin groups than in the control (p<0.001). In this respect, the mitochondrial depolarization and caspase-3 and caspase-9 levels were higher in the melatonin+AD, AD and AD+melatonin groups than in the control group (p<0.001). Additionally, the mitochondrial depolarization, caspase-3 and caspase-9 values were higher in the AD group than in the melatonin+AD and AD+melatonin groups (p<0.001), while mitochondrial depolarization and caspase-3 levels were lower in the melatonin+AD group than in the AD+melatonin group (p<0.001). However, in the same groups, there was no statistically significant difference in caspase-9 results. Additionally, the caspase-9 values were lower in the melatonin+AD group, AD group and AD+melatonin groups than in the melatonin+AD+AP18, AD+AP18 and AD+melatonin+AP18 groups, respectively (p<0.001 and p<0.05).
Conclusion: Our results suggest that melatonin may be an effective option in the treatment and prophylaxis of Alzheimer's disease by reducing cytosolic Ca2+ concentration, apoptosis and intracellular ROS through TRPA1 channels. Copyright:
© 2022 Turkish Neuropsychiatric Society.

Entities:  

Keywords:  Alzheimer’s disease; TRPA1; apoptosis; melatonin; neuroblastoma cells

Year:  2022        PMID: 36160083      PMCID: PMC9466640          DOI: 10.29399/npa.28183

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.066


  18 in total

1.  Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease.

Authors:  Egemen Savaskan; Mohammed A Ayoub; Rivka Ravid; Debora Angeloni; Franco Fraschini; Fides Meier; Anne Eckert; Franz Müller-Spahn; Ralf Jockers
Journal:  J Pineal Res       Date:  2005-01       Impact factor: 13.007

2.  Genetic deletion of TRPA1 receptor attenuates amyloid beta- 1-42 (Aβ1-42)-induced neurotoxicity in the mouse basal forebrain in vivo.

Authors:  M Payrits; E Borbely; S Godo; D Ernszt; A Kemeny; J Kardos; E Szoke; E Pinter
Journal:  Mech Ageing Dev       Date:  2020-05-28       Impact factor: 5.432

Review 3.  Sleep and Alzheimer's disease.

Authors:  Laure Peter-Derex; Pierre Yammine; Hélène Bastuji; Bernard Croisile
Journal:  Sleep Med Rev       Date:  2014-04-03       Impact factor: 11.609

Review 4.  Actions of melatonin in the reduction of oxidative stress. A review.

Authors:  R J Reiter; D X Tan; C Osuna; E Gitto
Journal:  J Biomed Sci       Date:  2000 Nov-Dec       Impact factor: 8.410

5.  N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease.

Authors:  Xavier Gironès; Arantxa Guimerà; Celia-Z Cruz-Sánchez; Arantxa Ortega; Noboyuki Sasaki; Zenji Makita; José Vivente Lafuente; Raj Kalaria; Félix F Cruz-Sánchez
Journal:  Free Radic Biol Med       Date:  2004-05-15       Impact factor: 7.376

6.  Caveolin-1 Regulates the P2Y2 Receptor Signaling in Human 1321N1 Astrocytoma Cells.

Authors:  Namyr A Martinez; Alondra M Ayala; Magdiel Martinez; Freddyson J Martinez-Rivera; Jorge D Miranda; Walter I Silva
Journal:  J Biol Chem       Date:  2016-04-18       Impact factor: 5.157

Review 7.  ITH12410/SC058: a new neuroprotective compound with potential in the treatment of Alzheimer's disease.

Authors:  Alejandro Romero; Javier Egea; Gema C González-Muñoz; Ma Dolores Martín de Saavedra; Laura del Barrio; María Isabel Rodríguez-Franco; Santiago Conde; Manuela G López; Mercedes Villarroya; Cristóbal de los Ríos
Journal:  ACS Chem Neurosci       Date:  2014-07-15       Impact factor: 4.418

8.  Synergic Effects of Doxorubicin and Melatonin on Apoptosis and Mitochondrial Oxidative Stress in MCF-7 Breast Cancer Cells: Involvement of TRPV1 Channels.

Authors:  Pınar Aslan Koşar; Mustafa Nazıroğlu; İshak Suat Övey; Bilal Çiğ
Journal:  J Membr Biol       Date:  2015-11-02       Impact factor: 1.843

9.  TRPA1 channels promote astrocytic Ca2+ hyperactivity and synaptic dysfunction mediated by oligomeric forms of amyloid-β peptide.

Authors:  Anthony Bosson; Adrien Paumier; Sylvie Boisseau; Muriel Jacquier-Sarlin; Alain Buisson; Mireille Albrieux
Journal:  Mol Neurodegener       Date:  2017-07-06       Impact factor: 14.195

Review 10.  Melatonin: Pharmacology, Functions and Therapeutic Benefits.

Authors:  Sylvie Tordjman; Sylvie Chokron; Richard Delorme; Annaëlle Charrier; Eric Bellissant; Nemat Jaafari; Claire Fougerou
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.